Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria
Antimicrobial resistance (AMR) has become a major and escalating global health threat, undermining the effectiveness of current antibiotic and antimicrobial therapies. The rise of multidrug-resistant bacteria has led to increasingly difficult-to-treat infections, resulting in higher morbidity, morta...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563450/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850038616316706816 |
|---|---|
| author | Wenwen Ding Wenwen Ding Yiwen Cheng Xia Liu Zhangcheng Zhu Lingbin Wu Jie Gao Wenhui Lei Yating Li Xin Zhou Xin Zhou Xin Zhou Xin Zhou Jian Wu Yongtao Gao Yongtao Gao Zongxin Ling Ruilai Jiang |
| author_facet | Wenwen Ding Wenwen Ding Yiwen Cheng Xia Liu Zhangcheng Zhu Lingbin Wu Jie Gao Wenhui Lei Yating Li Xin Zhou Xin Zhou Xin Zhou Xin Zhou Jian Wu Yongtao Gao Yongtao Gao Zongxin Ling Ruilai Jiang |
| author_sort | Wenwen Ding |
| collection | DOAJ |
| description | Antimicrobial resistance (AMR) has become a major and escalating global health threat, undermining the effectiveness of current antibiotic and antimicrobial therapies. The rise of multidrug-resistant bacteria has led to increasingly difficult-to-treat infections, resulting in higher morbidity, mortality, and healthcare costs. Tackling this crisis requires the development of novel antimicrobial agents, optimization of current therapeutic strategies, and global initiatives in infection surveillance and control. Recent studies highlight the crucial role of the human gut microbiota in defending against AMR pathogens. A balanced microbiota protects the body through mechanisms such as colonization resistance, positioning it as a key ally in the fight against AMR. In contrast, gut dysbiosis disrupts this defense, thereby facilitating the persistence, colonization, and dissemination of resistant pathogens. This review will explore how gut microbiota influence drug-resistant bacterial infections, its involvement in various types of AMR-related infections, and the potential for novel microbiota-targeted therapies, such as fecal microbiota transplantation, prebiotics, probiotics, phage therapy. Elucidating the interactions between gut microbiota and AMR pathogens will provide critical insights for developing novel therapeutic strategies to prevent and treat AMR infections. While previous reviews have focused on the general impact of the microbiota on human health, this review will specifically look at the latest research on the interactions between the gut microbiota and the evolution and spread of AMR, highlighting potential therapeutic strategies. |
| format | Article |
| id | doaj-art-5f8c61b9a7e643c2912b410d9312e5fe |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-5f8c61b9a7e643c2912b410d9312e5fe2025-08-20T02:56:33ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-03-011610.3389/fimmu.2025.15634501563450Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteriaWenwen Ding0Wenwen Ding1Yiwen Cheng2Xia Liu3Zhangcheng Zhu4Lingbin Wu5Jie Gao6Wenhui Lei7Yating Li8Xin Zhou9Xin Zhou10Xin Zhou11Xin Zhou12Jian Wu13Yongtao Gao14Yongtao Gao15Zongxin Ling16Ruilai Jiang17Department of Anesthesiology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, ChinaMedical School of Nantong University, Nantong, Jiangsu, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, ChinaDepartment of Intensive Care Unit, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, ChinaDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou, Zhejiang, ChinaDepartment of Intensive Care Unit, Lishui Second People’s Hospital, Lishui, Zhejiang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, ChinaJinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, ChinaDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, United StatesStanford Center for Genomics and Personalized Medicine, Stanford, CA, United States0Stanford Diabetes Research Center, Stanford, CA, United States1The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States2Department of Clinical Laboratory, Suzhou Municipal Hospital, Suzhou, Jiangsu, ChinaDepartment of Anesthesiology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, ChinaMedical School of Nantong University, Nantong, Jiangsu, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, ChinaDepartment of Intensive Care Unit, Lishui Second People’s Hospital, Lishui, Zhejiang, ChinaAntimicrobial resistance (AMR) has become a major and escalating global health threat, undermining the effectiveness of current antibiotic and antimicrobial therapies. The rise of multidrug-resistant bacteria has led to increasingly difficult-to-treat infections, resulting in higher morbidity, mortality, and healthcare costs. Tackling this crisis requires the development of novel antimicrobial agents, optimization of current therapeutic strategies, and global initiatives in infection surveillance and control. Recent studies highlight the crucial role of the human gut microbiota in defending against AMR pathogens. A balanced microbiota protects the body through mechanisms such as colonization resistance, positioning it as a key ally in the fight against AMR. In contrast, gut dysbiosis disrupts this defense, thereby facilitating the persistence, colonization, and dissemination of resistant pathogens. This review will explore how gut microbiota influence drug-resistant bacterial infections, its involvement in various types of AMR-related infections, and the potential for novel microbiota-targeted therapies, such as fecal microbiota transplantation, prebiotics, probiotics, phage therapy. Elucidating the interactions between gut microbiota and AMR pathogens will provide critical insights for developing novel therapeutic strategies to prevent and treat AMR infections. While previous reviews have focused on the general impact of the microbiota on human health, this review will specifically look at the latest research on the interactions between the gut microbiota and the evolution and spread of AMR, highlighting potential therapeutic strategies.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563450/fullgut microbiotaantimicrobial resistancecolonization resistancebacteriophageprobiotics |
| spellingShingle | Wenwen Ding Wenwen Ding Yiwen Cheng Xia Liu Zhangcheng Zhu Lingbin Wu Jie Gao Wenhui Lei Yating Li Xin Zhou Xin Zhou Xin Zhou Xin Zhou Jian Wu Yongtao Gao Yongtao Gao Zongxin Ling Ruilai Jiang Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria Frontiers in Immunology gut microbiota antimicrobial resistance colonization resistance bacteriophage probiotics |
| title | Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria |
| title_full | Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria |
| title_fullStr | Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria |
| title_full_unstemmed | Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria |
| title_short | Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria |
| title_sort | harnessing the human gut microbiota an emerging frontier in combatting multidrug resistant bacteria |
| topic | gut microbiota antimicrobial resistance colonization resistance bacteriophage probiotics |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563450/full |
| work_keys_str_mv | AT wenwending harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT wenwending harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT yiwencheng harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT xialiu harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT zhangchengzhu harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT lingbinwu harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT jiegao harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT wenhuilei harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT yatingli harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT xinzhou harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT xinzhou harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT xinzhou harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT xinzhou harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT jianwu harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT yongtaogao harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT yongtaogao harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT zongxinling harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria AT ruilaijiang harnessingthehumangutmicrobiotaanemergingfrontierincombattingmultidrugresistantbacteria |